SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis
7 references·0 citing·25 second hop
Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis (2010)Accounting for the Drug Life Cycle and Fu…Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II (2009)Good Research Practices for M…The NICE Cost-Effectiveness Threshold (2008)The NICE Cost-Effectiveness T…Future Drug Prices and Cost-Effectiveness Analyses (2008)Future Drug Prices and Cost-E…The Pharmaceutical Price Regulation Scheme (2007)The Pharmaceutical Price Regu…International society for pharmacoeconomics and outcomes research (2006)International society for pha…Theoretical Foundations of Cost-Effectiveness Analysis (1996)Theoretical Foundations of Co…Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Brand Loyalty, Entry, and Pri…Industrial Market Structure and Economic Performance. (1971)Product differentiation advantages of pioneering brands (1980)The economic analysis of advertising (2005)Chapter 28 The Economic Analysis of Advertising (2007)Killer Acquisitions (2020)Cost-Effectiveness in Health and Medicine (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)Decision Modelling For Health Economic Evaluation (2006)A Contribution to the Theory of Taxation (1927)Social Costs of Monopoly and Regulation (1974)Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan (2016)A global comparison of the cost of patented cancer drugs in relation to global differences in wealth (2017)An overview of the perspectives used in health economic evaluations (2024)Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada (2008)Valuing Health States for Use in Cost-Effectiveness Analysis (2008)Health Technology Funding Decision-Making Processes Around the World (2011)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)The cost-effectiveness of digital health interventions: A systematic review of the literature (2022)Pharmaceutical Pricing Policies in a Global Market (2008)Pharmaceutical Risk-Sharing Agreements (2008)International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug Programs (2012)Equity and the economic evaluation of healthcare (2001)Cost-Effectiveness And Evidence Evaluation As Criteria For Coverage Policy (2004)The Role Of Costs In Comparative Effectiveness Research (2010)
this work references cited by second hop

References

  • 2008The NICE Cost-Effectiveness Threshold868 cited
  • 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited
  • 2009Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II203 cited
  • 1996Theoretical Foundations of Cost-Effectiveness Analysis141 cited
  • 2007The Pharmaceutical Price Regulation Scheme99 cited
  • 2006International society for pharmacoeconomics and outcomes research92 cited
  • 2008Future Drug Prices and Cost-Effectiveness Analyses57 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work